Pharmaceutical Regulatory Documentation and Dossier Support

Pharmaceutical Regulatory Documentation and Dossier Support

A medicine cannot be sold until a regulator approves it. Whether a product is launched in India or exported to another country, the marketing authorisation holder must submit evidence that the product is safe, effective and manufactured to consistent quality. For most partners working with a contract manufacturer, the largest part of that evidence comes from the manufacturing site: how the product is made, how it is tested and how stable it is. 

Kilitch Healthcare supports partners with the manufacturing and quality documentation needed for regulatory submissions. Our experience with sterile injectables, ophthalmic products and other specialised dosage forms helps partners prepare complete, well-organised dossiers and avoid delays in registration. 

Why Documentation Decides Speed to Market

Many product launches are delayed not by manufacturing problems but by documentation gaps. Common issues include: 

  • Missing or incomplete stability data for the target market’s climatic conditions. 
  • Inconsistent specifications between the dossier and batch records. 
  • Insufficient process validation evidence for sterile processes. 
  • Unclear descriptions of manufacturing steps and controls. 
  • Outdated GMP certificates or site information. 
  • Queries from regulators that cannot be answered quickly. 

Each gap can add months to an approval timeline. Planning documentation alongside development and technology transfer is the most effective way to avoid this. 

The Common Technical Document Format

Many regulators, including those in India and numerous export markets, accept or require dossiers in the Common Technical Document (CTD) format. CTD organises information into five modules: 

Module 

Content 

Typical manufacturing contribution 

Module 1 

Regional administrative information 

Site licences, GMP certificates, labelling drafts 

Module 2 

Summaries and overviews 

Quality overall summary based on Module 3 data 

Module 3 

Quality 

Composition, manufacturing process, controls, specifications, validation, stability 

Module 4 

Non-clinical study reports 

Usually literature-based for generics 

Module 5 

Clinical study reports 

Bioequivalence or clinical data where required 

 For most generic sterile and ophthalmic products, Module 3 is where the manufacturing partner’s input is most important. 

Module 3: What the Manufacturer Provides

Module 3 describes the drug substance and drug product in detail. For the drug product, it typically includes: 

  • Description and composition of the product and its container. 
  • Pharmaceutical development, explaining why the formulation and process were chosen. 
  • Manufacturer details and site information. 
  • Batch formula for commercial batches. 
  • Manufacturing process description with a flow diagram and process controls. 
  • Control of critical steps and intermediates. 
  • Process validation, including sterilisation and aseptic process validation for sterile products. 
  • Control of excipients, including specifications. 
  • Specifications and analytical procedures for the finished product. 
  • Validation of analytical procedures. 
  • Batch analyses showing results from representative batches. 
  • Container closure system description and suitability. 
  • Stability data supporting the proposed shelf life and storage conditions. 

Kilitch prepares and supplies the manufacturing and quality information for these sections, in coordination with the partner’s regulatory team. 

Sterile Products Need Extra Evidence

Regulators look especially closely at sterile products. Dossiers for injectables and eye drops usually need: 

  • Sterilisation validation, whether terminal sterilisation or sterile filtration. 
  • Aseptic process validation, including media fill results. 
  • Container closure integrity evidence. 
  • Endotoxin and sterility testing methods and results. 
  • Particulate matter testing. 
  • Extractables and leachables considerations for container components, where relevant. 

Our experience in sterile injectable manufacturing, aseptic pharmaceutical manufacturing and ophthalmic drug manufacturing helps us provide this evidence clearly. 

Stability Data for Target Markets

International stability guidelines classify countries into climatic zones. Regulators in hot and humid regions often expect long-term stability data at conditions representing those climates, along with accelerated data. Products must be tested in their final container to support the labelled shelf life. 

Because stability studies take time, they should be planned early. Kilitch considers target markets during formulation development and technology transfer so stability programmes match registration plans. 

Supporting Documents Beyond the Dossier

Document 

Typical use 

GMP certificate 

Proof of site compliance for registration and tenders 

Site master file 

Overview of facility, equipment and quality systems 

Certificate of pharmaceutical product (CoPP) 

Required by many importing countries 

Free sale certificate 

Shows the product is sold in the country of origin, where applicable 

Certificates of analysis 

Batch-level quality confirmation 

Samples for registration testing 

Required by some regulators 

Kilitch works with partners to arrange these documents according to each market’s rules. Our certifications are listed on our accreditations and certificates page. 

Handling Regulatory Queries

After submission, regulators often send questions. Fast, accurate responses keep the review moving. When queries relate to manufacturing, testing or stability, Kilitch’s technical and quality teams work with the partner to prepare responses, provide additional data and clarify processes. 

Post-Approval Changes

Registration is not the end of documentation. Changes to suppliers, batch size, equipment, process or specifications may need notification or approval in each market. Kilitch’s change control system helps identify when a change may affect registrations so partners can plan variations before implementation. 

Partnership Models That Include Documentation Support

Common Dossier Deficiencies in Sterile Products

Regulators frequently raise similar questions on sterile product dossiers. Being prepared for them speeds up approval: 

  • Justification of sterilisation method: why terminal sterilisation was or was not chosen. 
  • Filter validation: evidence that the sterilising filter is compatible with the product and retains bacteria under process conditions. 
  • Media fill coverage: whether media fills represent the actual container, line and process. 
  • Hold times: validation of maximum times between compounding, filtration and filling. 
  • Container closure integrity: data showing the container remains sealed throughout shelf life. 
  • Impurity profiles: identification and limits for degradation products. 

Kilitch prepares supporting data on these topics so partners can respond confidently. 

Country-Specific Requirements

While CTD provides a common structure, each country adds its own requirements. Some require local agents, specific administrative forms or samples for testing. Others ask for prices, labelling in local languages or certificates legalised by embassies. Certain regulators conduct site inspections before approval. Understanding these differences early helps partners plan timelines and budgets realistically. Kilitch shares its experience of common requirements with partners and adapts manufacturing documentation to suit each submission. 

Dossier Maintenance

Approved dossiers must be kept up to date with renewals, variations and periodic reports, so documentation support continues throughout a product’s life. 

Working with Your Regulatory Team

Successful submissions depend on close cooperation between the manufacturer and the partner’s regulatory specialists. At project start, Kilitch and the partner agree on target markets, dossier format, timelines and responsibilities. Draft documents are shared for review, comments are resolved, and final versions are issued in a consistent format. Regular meetings during the submission and review period ensure that any regulator questions are answered quickly. This collaborative approach reduces rework and helps products reach approval sooner. 

Frequently Asked Questions

Does Kilitch submit dossiers to regulators? 

Submissions are usually made by the marketing authorisation holder. Kilitch provides the manufacturing and quality documentation needed for those submissions. 

What is Module 3 of a CTD dossier? 

It is the quality module, describing composition, manufacturing, controls, specifications, validation and stability. 

Why is stability data so important? 

It supports the product’s shelf life and storage conditions, and regulators require it for approval. 

What extra data do sterile products need? 

Typically sterilisation and aseptic process validation, container closure integrity and sterility, endotoxin and particulate testing. 

Can Kilitch help answer regulator queries? 

Yes. Our technical and quality teams support responses to manufacturing-related queries. 

Plan Your Registration with Kilitch

Tell us about your product and target markets so we can plan manufacturing and documentation together. Contact Kilitch Healthcare or explore our services.